Home > Lung Cancer
    • FILTER YOUR SEARCH
    Content Type:

    • Lung Cancer

    An Introduction to Lung Cancer

    In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Lung Cancer Content

    Lung Cancer
    touchEXPERT OPINIONS
    Moving MET into the clinic: Latest evidence for MET inhibitors in NSCLC
    CME ACCREDITED Dr Enriqueta Felip, Dr Rebecca S Heist, Dr Takashi Seto Watch Time: 37 mins Available in:

    Watch leading experts review the latest clinical data from ASCO 2021 on the role of MET inhibitors in NSCLC and the importance of identifying patients who may benefit from a targeted approach

    Learning objectives
    Learning Objectives
    • Recall the latest efficacy data from MET-inhibitor clinical trials in NSCLC
    • Describe diagnostic methods for the identification of MET exon 14 skipping mutations and MET amplification
    • Discuss practical adverse event management with MET inhibitors in the clinic
    Lung Cancer
    Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer
    Matthew Z Guo, Kristen A Marrone, Alexander Spira

    touchREVIEWS in Oncology & Haematology. 2021;17(1):Online ahead of journal publication

    Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]

    Lung Cancer
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Patients with Non-small Cell Lung Cancer of Squamous Histology: Focus on Afatinib
    Noemi Reguart, Roxana Reyes

    touchREVIEWS in Oncology & Haematology. 2021;17(1): Online ahead of journal publication

    The treatment of patients with non-small cell lung cancer (NSCLC) has seen significant advances in the past decade, with the availability of multiple targeted therapy agents for oncogenic-driven non-squamous NSCLC and the advent of immunotherapy that has completely revolutionized the treatment of patients without oncogenic drivers. Consequently, the lives of patients with NSCLC have significantly […]

    Immunotherapy, Lung Cancer
    touchPANEL DISCUSSION
    Targeting IL-1β in NSCLC: What does the future hold?
    Dr Pilar Garrido, Dr Barbara Melosky, Dr Alastair Greystoke Watch Time: 30 mins Available in:

    Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade.

    Learning objectives
    Learning Objectives
    • Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations
    • Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours
    • Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved
    Lung Cancer
    touchTALKS
    A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC
    Dr Stephen Liu Watch Time: 27 mins Available in:

    Dr Stephen Liu presents the latest data and future directions of targeted therapy within the rapidly evolving treatment landscape for patients with early-stage NSCLC.

    Learning objectives
    Learning Objectives
    • Recall the latest efficacy and safety data for EGFR-TKIs for patients with early-stage EGFR-mutant NSCLC
    • Describe how the evolving use of EGFR-TKIs may impact the current recommendations for mutation testing in NSCLC
    • Discuss how EGFR-TKIs may be incorporated into the evolving treatment pathway for early-stage NSCLC, now and in the future
    Lung Cancer
    touchEXPERT OPINIONS
    Current treatment paradigm and future prospects for extensive-stage small cell lung cancer in the relapsed setting
    CME ACCREDITED Prof. Taofeek Owonikoko, Dr Viola Zhu, Prof. Giuseppe Giaccone Watch Time: 42 mins

    Watch three oncology specialists discuss the latest advances in the treatment of extensive-stage small cell lung cancer (SCLC).

    Learning objectives
    Learning Objectives
    • Summarize the current treatment recommendations for SCLC and how they are evolving as new agents emerge
    • Evaluate the efficacy and safety of emerging agents for relapsed SCLC
    • Describe emerging treatment options and ongoing clinical trials for relapsed SCLC
    Breast Cancer, Genitourinary Cancers, Lung Cancer, Gastric Cancer
    touchEXPERT OPINIONS
    Antibody-drug conjugates for solid tumours: Current understanding and future directions
    CME ACCREDITED Dr Giuseppe Curigliano Watch Time: 19 mins

    Watch Prof. Giuseppe Curigliano discuss the latest advances in the antibody-drug conjugates for the treatment of solid tumours.

    Learning objectives
    Learning Objectives
    • Evaluate the efficacy and safety data for emerging ADCs in solid tumours
    • Discuss how emerging ADCs may be incorporated into the treatment paradigm for patients with solid tumours
    • Summarise novel ADCs and the ongoing clinical trials in patients with solid tumours
    Lung Cancer
    MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
    Rashmi Shah, Deepu Alex, Zhaolin Xu

    Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100

    Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]

    Lung Cancer
    Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options
    Lawrence Berk

    Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95

    Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as pain and dysphagia, which can negatively impact patient quality of life.1 Severe esophagitis requires parenteral […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72